Zydus Cadila acquires US-based specialty drugs player Sentynl

With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $8 bn

Zydus Cadila acquired Sentynl Therapeutics Inc a US-based specialty pharma company specialised in marketing of products in the pain management segment for an undisclosed sum. 

The transaction will be EPS accretive. 

"With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $8 billion. It gains access to the speciality distribution network and a large prescriber base. This acquisition will also enable the Zydus group to leverage its existing assets in the US," a company statement here said. 

Pankaj Patel, chairman and managing director, Zydus Cadila, said: “We have always looked at opportunities that